Charles River Laboratories | CRL - Assets


Charles River Laboratories reported $7.73B in Assets for its fiscal quarter ending in March of 2026.





Assets Change Date
Agilent USD 13.07B 252M Mar/2026
Align Technology USD 6.31B 80.48M Mar/2026
Bio-Rad Laboratories USD 9.79B 786.5M Mar/2026
Bruker USD 6.13B 110.7M Mar/2026
Cardinal Health USD 56.69B 1.39B Mar/2026
Charles River Laboratories USD 7.73B 594.89M Mar/2026
Cigna USD 153.27B 4.65B Mar/2026
Concord Medical Services Hldg CNY 6.73B 663.4M Jun/2025
CVS Health USD 252.97B 564M Mar/2026
Danaher USD 83.54B 80M Mar/2026
Dentsply International USD 5.23B 200M Mar/2026
Elevance Health USD 125.83B 4.33B Mar/2026
Humana USD 55.28B 6.37B Mar/2026
Illumina USD 6.56B 85M Mar/2026
Incyte USD 7.34B 381.14M Mar/2026
Intrexon USD 73.16M 77.88M Jun/2024
IQVIA Holdings USD 29.68B 269M Mar/2026
Laboratory Of America USD 19.09B 694.4M Mar/2026
Lakefront Biotherapeutics EUR 3.37B 34.09M Mar/2026
Lonza CHF 18.97B 164M Dec/2025
McKesson USD 82.32B 1.87B Mar/2026
Merck EUR 53.07B 1.54B Mar/2026
Mettler Toledo International USD 3.67B 43.73M Mar/2026
Novartis USD 118.53B 7.58B Mar/2026
Pfizer USD 207.62B 542M Mar/2026
Quest Diagnostics USD 16.67B 448M Mar/2026
Revvity USD 12B 171.82M Mar/2026
Thermo Fisher Scientific USD 113.28B 2.94B Mar/2026
United Therapeutics USD 6.71B 1.17B Mar/2026
UnitedHealth USD 312.64B 3.06B Mar/2026
Veradigm USD 1.5B 185.94M Dec/2022
Waters USD 24.53B 19.45B Mar/2026
West Pharmaceutical Services USD 4.11B 160.2M Mar/2026